000 | 02191 a2200589 4500 | ||
---|---|---|---|
005 | 20250514021511.0 | ||
264 | 0 | _c20020522 | |
008 | 200205s 0 0 eng d | ||
022 | _a0379-0355 | ||
024 | 7 |
_a10.1358/mf.2001.23.7.662123 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aIzumo, N | |
245 | 0 | 0 |
_aLipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. _h[electronic resource] |
260 |
_bMethods and findings in experimental and clinical pharmacology _cSep 2001 |
||
300 |
_a389-94 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aBone Morphogenetic Protein 2 |
650 | 0 | 4 |
_aBone Morphogenetic Proteins _xmetabolism |
650 | 0 | 4 |
_aCalcification, Physiologic _xdrug effects |
650 | 0 | 4 |
_aCalcium _xmetabolism |
650 | 0 | 4 | _aCell Line |
650 | 0 | 4 | _aCore Binding Factor Alpha 1 Subunit |
650 | 0 | 4 | _aCore Binding Factors |
650 | 0 | 4 |
_aFatty Acids, Monounsaturated _xpharmacology |
650 | 0 | 4 | _aFluvastatin |
650 | 0 | 4 |
_aGTPase-Activating Proteins _xantagonists & inhibitors |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xpharmacology |
650 | 0 | 4 | _aImmunohistochemistry |
650 | 0 | 4 |
_aIndoles _xpharmacology |
650 | 0 | 4 |
_aLovastatin _xanalogs & derivatives |
650 | 0 | 4 |
_aMevalonic Acid _xmetabolism |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aNeoplasm Proteins |
650 | 0 | 4 |
_aOsteoblasts _xcytology |
650 | 0 | 4 |
_aOsteogenesis _xdrug effects |
650 | 0 | 4 |
_aPhosphates _xpharmacology |
650 | 0 | 4 |
_aPolyisoprenyl Phosphates _xmetabolism |
650 | 0 | 4 |
_aPravastatin _xpharmacology |
650 | 0 | 4 | _aProtein Prenylation |
650 | 0 | 4 | _aSesquiterpenes |
650 | 0 | 4 | _aSignal Transduction |
650 | 0 | 4 |
_aTranscription Factors _xmetabolism |
650 | 0 | 4 |
_aTransforming Growth Factor beta _xmetabolism |
650 | 0 | 4 | _aTumor Cells, Cultured |
700 | 1 | _aFujita, T | |
700 | 1 | _aNakamuta, H | |
700 | 1 | _aKoida, M | |
773 | 0 |
_tMethods and findings in experimental and clinical pharmacology _gvol. 23 _gno. 7 _gp. 389-94 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1358/mf.2001.23.7.662123 _zAvailable from publisher's website |
999 |
_c11683927 _d11683927 |